The pharma wholesale and distribution market is estimated to grow at a CAGR of 5% in the first half of the forecast period. The market is estimated to reach a revenue of $1,447bn in 2025. In 2018, the branded drugs submarket held 78% of the pharma wholesale and distribution market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 217-page report you will receive 135 charts– all unavailable elsewhere.
The 217-page report provides clear detailed insight into the pharma wholesale and distribution market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Pharma Wholesale and Distribution Market from 2020-2030
• Forecast of the Global Pharma Wholesale and Distribution market by Category:
• Generic Drugs
• Branded Drugs
• Others
• This report provides individual revenue forecasts to 2030 for these national markets:
• US
• Germany
• France
• Italy
• Spain
• UK
• Japan
• China
• Brazil
• India
• Russia
• RoW
Each National Market is further segmented into generic drugs, branded drugs and others
• Our study discusses the selected leading companies that are the major players in the global pharma and wholesale distribution market:
• Alfresa Holdings
• AmerisourceBergen
• Cardinal Health
• CR Pharmaceuticals
• CuraScript SD
• McKesson
• Medipal Holdings Corporation
• Morris and Dickson
• Mutual Drug Company
• PHOENIX Group
• Shanghai Fosun Pharmaceuticals
• Sinopharm
• Suzuken
• Walgreens Boots Alliance
• This report provides a SWOT and STEP analysis of the pharma wholesale and distribution market.
Visiongain’s study is intended for anyone requiring commercial analyses for the pharma wholesale and distribution market. You find data, trends and predictions.
Buy our report today Pharma Wholesale and Distribution Market Forecasts 2020-2030: Branded Drugs, Generic Drugs, US, China, Japan, Germany, France, Brazil, Italy, Spain, UK, India, Russia, RoW.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Global Pharma Wholesale and Distribution Industry and Market Overview
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to Pharma Wholesale and Distribution
2.1 The Role of Pharmaceutical Wholesalers: The Middlemen of the Pharmaceutical Industry
2.1.1 Full-Line Wholesalers (FLWs)
2.1.2 Short-Line Wholesalers (SLWs)
2.2 The Chain of Distribution: Wholesalers vs. Logistic Service Providers
2.2.1 Secondary Wholesalers
2.2.2 Direct-to-Pharmacy (DTP) Distribution is Becoming More Prevalent
2.2.3 Major Wholesalers: Distribution of a Large Number of Products to Generate High Profits
2.2.4 Distribution from Large to Small Wholesalers: A Lengthy Distribution Chain
2.2.5 Pharmacy Benefit Managers
2.3 Generative Revenue and Profit
2.3.1 Forward Buying to Avoid Price Increases
2.3.2 Fee-for-Service: A Clear Pricing Structure
2.3.2.1 Inventory Management Agreements
2.3.3 Discounts: Incentives for Prompt Payment or Bulk Purchases
2.3.4 Reimbursement and Wholesalers
2.3.5 Clawback: The Recovery of Reimbursement Costs by Governments
2.3.6 Parallel Trade: Different Attitudes in Europe and the US
3. The World Pharmaceutical Wholesale and Distribution Market: 2020-2030
3.1 The World Pharmaceutical Wholesale and Distribution Market, Restricted by Government Price Reductions and Generic Substitution
3.2 The Pharmaceutical Wholesale and Distribution Industry: World Market Forecast, 2018-2030
3.3 Branded and Generic Drugs: Revenue vs. Profit, 2018-2030
3.3.1 Branded and Generic Drugs: Revenue Generation, 2017
3.3.2 Branded Drugs: Revenue Forecast, 2018-2030
3.3.3 Generic Drugs: Revenue Forecast, 2018-2030
4. Pharmaceutical Wholesale and Distribution Industry: Leading National Markets, 2020-2030
4.1 The Leading National Markets: the US Dominates in 2018
4.2 The Future of the Leading National Markets: Will the US Continue to Dominate the Market?
4.3 The US Pharma Wholesale and Distribution Market
4.3.1 Specialty Pharmacies Hinders the Growth of Wholesaler’s Business
4.3.2 The Budget Control Act and its Effect on the US Wholesale and Distribution Industry
4.3.3 Legislation to Prevent Counterfeit Drugs Can Differ Between States
4.3.4 An Increase in Fee-For-Service Activity
4.3.5 Pharma Wholesale and Distribution Market in the US: Market Forecast, 2018-2030
4.4 The Leading European (EU5) Pharma Wholesale and Distribution Markets
4.4.1 The Difference Between the US and European Markets
4.4.2 State-Funded Healthcare and Reimbursement
4.4.3 EU5: Market Forecast, 2018-2030
4.4.4 Germany: Pharma Wholesale and Distribution Market
4.4.4.1 Healthcare Reform
4.4.4.2 Germany: Reform of AMNOG Pharmaceutical Rebate Law
4.4.4.3 Germany Pharma Wholesale and Distribution Market Forecast, 2018-2030
4.4.5 France: Pharma Wholesale and Distribution Market
4.4.5.1 France: Social Security Finance Bill 2015
4.4.5.2 France: Pharma Wholesale and Distribution Market Forecast, 2018-2030
4.4.6 Italy: Pharma Wholesale and Distribution Market
4.4.6.1 Italy: Pharma Wholesale and Distribution Market Forecast, 2018-2030
4.4.7 Spain: Pharma Wholesale and Distribution Market
4.4.7.1 Spain: Pharma Wholesale and Distribution Market Forecast, 2018-2030
4.4.8 UK: Pharma Wholesale and Distribution Market
4.4.8.1 Price Cuts in the UK
4.4.8.2 Surge in Price of Generic Drugs
4.4.8.3 UK: Pharma Wholesale and Distribution Market Forecast, 2018-2030
4.5 Japan: Pharma Wholesale and Distribution Market
4.5.1 Drug Pricing and Performing Fees in Japan
4.5.2 Japan: Pharma Wholesale and Distribution Market Forecast, 2018-2030
4.6 China: Pharma Wholesale and Distribution Market
4.6.1 China: Leading Pharma Wholesale and Distribution Companies
4.6.2 China: Pharma Wholesale and Distribution Market Forecast, 2018-2030
4.7 Brazil: Pharma and Wholesale Distribution Market
4.7.1 Drug Price Controls in Brazil
4.7.2 Brazil: Pharma Wholesale and Distribution Market Forecast, 2018-2030
4.8 India: Pharma Wholesale and Distribution Market
4.8.1 India: Pharma Wholesale and Distribution Market Forecast, 2018-2030
4.9 Russia: Pharma Wholesale and Distribution Market, 2016
4.9.1 Drug Pricing Controls in Russia
4.9.2 Market Trends in Russia
4.9.3 Russia: Pharma Wholesale and Distribution Market Forecast, 2018-2030
4.10 Conclusion
5. Leading Pharma Wholesalers and Distributors:
5.1 The Leading Pharma Wholesalers and Distribution Companies, 2018
5.2 Leading Pharma Wholesale and Distribution Companies, Drivers and Restraints
5.3 McKesson Corporation
5.3.1 McKesson: Sales and Recent Performance Analysis, 2019
5.3.2 Future Strategies: Consummate Acquisitions to Complement Existing Business or Expand Businesses
5.3.3 McKesson: Recent Developments, 2016-2019
5.3.3.1 Acquisition of Medical Specialties Distributors
5.3.3.2 Acquisition of GMD Distribution, Inc.
5.3.3.3 Partnership with Walmart
5.3.3.4 Acquisition of UDG’s Irish Pharmaceutical Distribution Business
5.4 Cardinal Health
5.4.1 Cardinal Health: Sales and Recent Performance Analysis, 2018
5.4.2 Will CVS Joint Venture and Acquisitions Stimulate Future Growth?
5.4.3 Cardinal Health: Recent Developments, 2016-2019
5.4.3.1 Closing of pharmaceutical packaging center and a distribution warehouse
5.4.3.2 Divestiture of Cardinal Health’s China Business
5.5 AmerisourceBergen
5.5.1 AmerisourceBergen: Sales and Recent Performance Analysis, 2018
5.5.2 Will Contracts with Walgreens and Alliance Boots Drive Future Growth?
5.5.3 AmerisourceBergen: Recent Developments, 2016-2019
5.5.3.1 Closing of California Distribution Center
5.5.3.2 Joint Venture with Profarma Distribuidora
5.5.3.3 Acquisition of H.D.Smith
5.6 Walgreens Boots Alliance
5.6.1 Walgreens Boots Alliance, Sales and Recent Performance Analysis, 2018
5.6.2 Walgreen Boots Alliance: Recent Developments, 2016-2019
5.7 Medipal Holdings Corporation
5.7.1 Medipal: Sales and Recent Performance Analysis, 2018
5.7.2 Future Strategies of Medipal Holdings Corporation: Revised Business Portfolio with Diverse Sources of Earnings
5.7.3 Medipal: Recent Developments, 2016-2019
5.8 Phoenix Group
5.8.1 The PHOENIX Group: Sales and Recent Performance Analysis, 2018
5.8.2 Future Strategies of the PHOENIX Group: Selective Acquisition
5.8.3 Phoenix Group: Recent Developments, 2016-2019
5.8.3.1 Acquisition of Farmexim S.A. and the Help Net Farma S.A.
5.9 Sinopharm Group Co. Ltd.
5.9.1 Sinopharm, Sales and Recent Performance Analysis, 2018
5.9.2 Future Strategies of Sinopharm: Provide Comprehensive Services and Wider Business Coverage
5.9.3 Sinopharm: Recent Developments, 2016-2019
5.10 Alfresa Holdings Corporation
5.10.1 Alfresa, Sales and Recent Performance Analysis, 2018
5.10.2 Alfresa: Recent Developments, 2016-2019
5.11 Suzuken Co., Ltd
5.11.1 Suzuken Co. Ltd, Sales and Recent Performance Analysis, 2018
5.11.2 Future Strategies of Suzuken CO., LTD: Five Growth Initiatives and Special Focus on Diabetes Field
5.11.3 Suzuken: Recent Developments, 2016-2019
5.11.3.1 Collaboration with Toho Holdings Co., Ltd.
5.11.3.2 Collaboration with World Courier
5.11.3.3 Agreement with AmerisourceBergen
5.12 Shanghai Fosun Pharmaceuticals Co. Ltd.
5.12.1 Shanghai Fosun Pharmaceuticals, Sales and Recent Performance Analysis, 2018
5.12.2 Future Strategies of Shanghai Fosun Pharma: Expansion of Three Leading Regions in China
5.12.3 Shanghai Fosun Pharmaceuticals: Recent Developments, 2016-2019
5.12.3.1 Acquisition of Cardinal Health’s China Business
5.12.3.2 Acquisition of Tridem Pharma
5.13 CR Pharmaceuticals
5.13.1 CR Pharmaceuticals: Sales and Recent Performance Analysis, 2018
5.13.2 CR Pharmaceuticals: Recent Developments
5.13.2.1 Strategic cooperation agreement with Novartis
5.13.2.2 Collaboration with China Merchants Bank and Shenzhen Qianhai WeBank
5.14 Morris and Dickson
5.14.1 Morris and Dickson: Sales and Recent Performance Analysis, 2018
5.14.2 Morris and Dickson: Recent Developments
5.14.3 Smith Drug Company
5.14.4 Smith Drug Company: Sales and Recent Performance Analysis, 2018
5.14.5 Smith Drug Company: Recent Developments
5.15 CuraScript SD
5.15.1 CuraScript SD: Sales and Recent Performance Analysis, 2018
5.15.2 CuraScript SD: Recent Developments
5.16 Mutual Drug Company
5.16.1 Mutual Drug Company: Sales and Recent Performance Analysis, 2018
5.16.2 Mutual Drug Company: Recent Developments
6. Qualitative Analysis of The Pharma Wholesale and Distribution Market
6.1 The Strengths and Weaknesses of the Pharma Wholesale and Distribution Market
6.1.1 The Insatiable Demand for Drugs: A Recession Proof Industry?
6.1.2 Wholesalers Do More than Deliver Drugs
6.1.2.1 Pre-Wholesaling: More Prevalent in Europe
6.1.2.2 Through Pre-Financing, Full-Line Wholesalers Finance the Entire Medicines Market
6.1.3 Large Companies Dominate the Market
6.1.4 Despite High Revenues, Profit Margins Are Low
6.1.5 Government-Induced Drug Price Pressures Restrict Profits
6.1.6 The Problem of Counterfeit Drugs
6.2 The Opportunities and Threats of the Pharma Wholesale and Distribution Market, 2018-2030
6.2.1 The Demand for Pharmaceuticals is Increasing
6.2.2 The Increasing Use of Specialty Drugs Will Drive Growth
6.2.3 The Increasing Use of Generic Drugs Will Limit Revenue but Drive Profit Generation
6.2.4 The Promotion of Drug Therapy in the US
6.2.5 Globalisation: The Major National Markets are Dominated by Few Companies
6.2.6 Increased Adoption of the DTP Distribution Model
6.2.6.1 DTP in Europe: The First Place the Scheme Has Taken Hold
6.2.6.2 DTP in the UK Since 1991
6.2.6.3 DTP in Poland: The Second European Country to Adopt the DTP Model
6.2.6.4 Further Expansion of the DTP Model
6.2.7 The Threat of Healthcare Budget Cuts
6.2.7.1 Healthcare Budget Cuts in Germany
6.2.7.2 Healthcare Budget Cuts in France
6.2.7.3 Healthcare Budget Cuts in Italy
6.2.7.4 Healthcare Budget Cuts in Spain
6.2.7.5 Healthcare Budget Cuts in the UK
6.2.8 Do Large Pharmacy Chains Pose a Threat?
6.2.8.1 Case Study: Walmart and the $4 Prescription Scheme
6.2.8.2 Vertical Integration of Wholesalers: A Response to the Threat of Pharmacy Chains
6.2.9 Does the Diversion and Re-Importation of Medicines Pose a Threat to the Industry?
6.2.10 The Threat of Industry Consolidation
6.3 Social, Technological, Economic and Political Factors Influencing the Market, 2018-2030 (STEP Analysis)
6.3.1 Political Factor: The Impact of Recent Regulatory Changes in the EU
6.3.2 Political Factor: Combating Counterfeit Medicines
6.3.2.1 The US and E-Pedigree: Becoming Law in California
6.3.2.2 Anti-Counterfeiting Strategies in Other Markets: The Chinese Government is Attempting to Address the Challenge
6.3.2.3 Serialisation for Wholesalers: Opportunity or a Challenge?
7. Conclusions
7.1 Specialty Drug Products to Drive Growth in the Pharma Wholesale and Distribution Market
7.2 The Leading National Pharma Wholesale and Distribution Markets
7.3 The Leading Companies in the Pharma Wholesale and Distribution Industry
7.4 Trends in the Pharma Wholesale and Distribution Industry
7.4.1 Generics Will Threaten Revenue Growth
7.4.2 Manufacturers Will Deliver More Drugs Directly
7.4.3 There Will Be Greater Demand for Specialty Medicines
7.4.4 Consolidation Will Drive Growth
7.4.5 Anti-Counterfeiting Demands Will Add to Wholesalers’ Costs
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
TABLE 2.1 USE OF DTP MODEL IN THE UK, 2007-2012
TABLE 3.1 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: WORLD MARKET FORECAST ($BN), AGR (%), CAGR (%), 2018-2030
TABLE 3.2 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: BRANDED DRUGS, GENERIC DRUGS AND OTHERS, REVENUE ($BN) FORECASTS, AGR (%), CAGR (%) AND MARKET SHARES (%), 2018-2030
TABLE 3.3 WHOLESALE AND DISTRIBUTION OF BRANDED DRUGS: REVENUE ($BN) AND MARKET SHARE (%) FORECAST, 2018-2030
TABLE 3.4 WHOLESALE AND DISTRIBUTION OF GENERIC DRUGS: REVENUE ($BN) AND MARKET SHARE (%) FORECAST, 2018-2030
TABLE 4.1 PHARMA WHOLESALE & DISTRIBUTION LEADING NATIONAL MARKETS: REVENUES ($BN) AND MARKET SHARE (%), 2018
Table 4.2 Pharma Wholesale & Distribution Leading National Markets: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2018-2030
TABLE 4.3 US PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.4 US PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.5 PRICE CONTROLS IN EUROPE, 2016
TABLE 4.6 EU5 PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECASTS, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.7 GERMAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.8 GERMAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.9 FRENCH PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.10 FRENCH PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.11 ITALIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.12 ITALIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.13 SPANISH PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.14 SPANISH PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.15 UK PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.16 UK PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.17 PERCENTAGE OF THE POPULATION AGES 60+ IN THE US, EUROPE, JAPAN, CHINA AND INDIA, 2015 AND 2030
TABLE 4.18 JAPANESE PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET: DRUG PRICE REVISION GROWTH (%), 2006-2016
TABLE 4.19 JAPANESE PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.20 JAPANESE PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.21 CHINESE PHARMA WHOLESALE & DISTRIBUTION: REVENUE ($BN) AND MARKET SHARES (%) OF LEADING COMPANIES, 2018
TABLE 4.22 CHINESE PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.23 CHINESE PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.24 BRAZILIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.25 BRAZILIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.26 INDIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.27 INDIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.28 RUSSIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
TABLE 4.29 RUSSIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
TABLE 5.1 LEADING COMPANIES IN THE PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET: REVENUES ($BN) AND MARKET SHARES (%), 2018
TABLE 5.2 MCKESSON: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2015-2019
TABLE 5.3 ACQUISITIONS BY MCKESSON, 2007-2019
TABLE 5.4 CARDINAL HEALTH: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
TABLE 5.5 SELECTED ACQUISITIONS BY CARDINAL HEALTH AND THEIR LINE OF BUSINESS, 2007-2019
TABLE 5.6 AMERISOURCEBERGEN: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
TABLE 5.7 ACQUISITIONS BY AMERISOURCEBERGEN AND THEIR LINE OF BUSINESS, 2007-2019
TABLE 5.8 WALGREENS BOOTS ALLIANCE: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
TABLE 5.9 MEDIPAL: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
TABLE 5.10 PHOENIX GROUP: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
TABLE 5.11 SINOPHARM: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
TABLE 5.12 ALFRESA: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
TABLE 5.13 SUZUKEN: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
TABLE 5.14 SHANGHAI FOSUN PHARMA: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
TABLE 5.15 CR PHARMACEUTICALS: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
TABLE 6.1 THE PHARMACEUTICAL W&D MARKET: STRENGTHS AND WEAKNESSES
TABLE 6.2 THE PHARMACEUTICAL W&D MARKET: OPPORTUNITIES AND THREATS, 2019-2030
TABLE 6.3 STRENGTHS AND WEAKNESSES OF THE DTP DISTRIBUTION MODEL
TABLE 6.4 ITR RATINGS AND CORRESPONDING REIMBURSEMENT RATES
TABLE 6.5 SOCIAL, TECHNOLOGICAL, ECONOMIC AND POLITICAL FACTORS INFLUENCING THE PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET (STEP ANALYSIS
List of Figures
FIGURE 2.1 ROUTES OF DRUG DISTRIBUTION
FIGURE 3.1 THE GLOBAL PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
FIGURE 3.2 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: WORLD MARKET FORECAST ($BN), 2018-2030
FIGURE 3.3 BRANDED DRUGS, GENERIC DRUGS, AND OTHERS: MARKET SHARES (%), 2018
FIGURE 3.4 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: WORLD MARKET FORECAST ($BN) BY CATEGORY, 2018-2030
FIGURE 3.5 BRANDED DRUGS, GENERIC DRUGS AND OTHERS: MARKET SHARES (%), 2025
FIGURE 3.6 BRANDED DRUGS, GENERIC DRUGS AND OTHERS: MARKET SHARES (%), 2030
FIGURE 3.7 WHOLESALE AND DISTRIBUTION OF BRANDED DRUGS, GENERIC DRUGS AND OTHERS: REVENUE FORECASTS ($BN), 2018-2030
FIGURE 3.8 WHOLESALE AND DISTRIBUTION OF BRANDED DRUGS: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 3.9 WHOLESALE AND DISTRIBUTION OF GENERIC DRUGS: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.1 PHARMA WHOLESALE & DISTRIBUTION LEADING NATIONAL MARKETS: SHARES (%), 2018
FIGURE 4.2 PHARMA WHOLESALE & DISTRIBUTION LEADING NATIONAL MARKETS: SHARES (%), 2025
FIGURE 4.3 PHARMA WHOLESALE & DISTRIBUTION LEADING NATIONAL MARKETS: SHARES (%), 2030
FIGURE 4.4 US PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET: SHARE (%), 2018
FIGURE 4.5 US PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.6 US PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.7 US PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
FIGURE 4.8 EU5 PHARMA WHOLESALE & DISTRIBUTION MARKET SHARES (%), 2018
FIGURE 4.9 EU5 PHARMA WHOLESALE & DISTRIBUTION MARKET SHARES (%), 2025
FIGURE 4.10 EU5 PHARMA WHOLESALE & DISTRIBUTION MARKET SHARES (%), 2030
FIGURE 4.11 EU5 PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECASTS, 2018-2030
FIGURE 4.12 EU PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
FIGURE 4.13 GERMAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.14 GERMAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.15 GERMAN PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
FIGURE 4.16 FRENCH PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.17 FRENCH PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.18 FRENCH PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
FIGURE 4.19 ITALIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.20 ITALIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.21 ITALIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS, 2017
FIGURE 4.22 SPANISH PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.23 SPANISH PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.24 SPANISH PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS, 2017
FIGURE 4.25 UK PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN), 2018-2030
FIGURE 4.26 UK PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.27 UK PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
FIGURE 4.28 PERCENTAGE OF THE POPULATION AGES 65+ IN THE US, EUROPE, JAPAN, CHINA AND INDIA, 2015 AND 2030
FIGURE 4.29 JAPANESE PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.30 JAPANESE PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.31 JAPANESE PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
FIGURE 4.32 CHINESE PHARMA WHOLESALE & DISTRIBUTION: MARKET SHARES (%), 2018
FIGURE 4.33 CHINESE PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.34 CHINESE PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.35 CHINESE PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
FIGURE 4.36 BRAZILIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.37 BRAZILIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.38 BRAZILIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
FIGURE 4.39 PHARMA WHOLESALE & DISTRIBUTION MODEL IN INDIA
FIGURE 4.40 INDIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.41 INDIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.42 INDIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
FIGURE 4.43 RUSSIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.44 RUSSIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
FIGURE 4.45 RUSSIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
FIGURE 5.1 LEADING PHARMACEUTICAL WHOLESALE AND DISTRIBUTION COMPANIES: MARKET SHARES (%), 2018
FIGURE 5.2 LEADING PHARMACEUTICAL W&D COMPANIES: DRIVERS AND RESTRAINTS
FIGURE 5.3 MCKESSON: HISTORICAL REVENUE ($BN), 2015-2019
FIGURE 5.4 MCKESSON: DRIVERS AND RESTRAINTS
FIGURE 5.6 CARDINAL HEALTH: HISTORICAL REVENUE ($BN), 2014-2018
FIGURE 5.7 CARDINAL HEALTH: DRIVERS AND RESTRAINTS
FIGURE 5.8 AMERISOURCEBERGEN: HISTORICAL REVENUE ($BN), 2014-2018
FIGURE 5.9 AMERISOURCEBERGEN: DRIVERS AND RESTRAINTS
FIGURE 5.10 WALGREENS BOOTS ALLIANCE: HISTORICAL REVENUE ($BN), 2014-2018
FIGURE 5.11 WALGREEN BOOTS ALLIANCE: DRIVERS AND RESTRAINTS
FIGURE 5.12 MEDIPAL: HISTORICAL REVENUE ($BN), 2014-2018
FIGURE 5.13 MEDIPAL HOLDINGS: DRIVERS AND RESTRAINTS
FIGURE 5.14 PHOENIX GROUP: HISTORICAL REVENUE ($BN), 2014-2018
FIGURE 5.15 PHOENIX GROUP DRIVERS AND RESTRAINTS
FIGURE 5.16 SINOPHARM: HISTORICAL REVENUE ($BN), 2014-2018
FIGURE 5.17 SINOPHARM GROUP: DRIVERS AND RESTRAINTS
FIGURE 5.18 ALFRESA: HISTORICAL REVENUE ($BN), 2014-2018
FIGURE 5.19 ALFRESA: DRIVERS AND RESTRAINTS
FIGURE 5.20 SUZUKEN: HISTORICAL REVENUE ($BN), 2014-2018
FIGURE 5.21 SUZUKEN: DRIVERS AND RESTRAINTS
FIGURE 5.22 SHANGHAI FOSUN PHARMA: HISTORICAL REVENUE ($BN), 2014-2018
FIGURE 5.23 SHANGHAI FOSUN PHARMACEUTICALS: DRIVERS AND RESTRAINTS
FIGURE 5.24 CR PHARMACEUTICALS: HISTORICAL REVENUE ($BN), 2014-2018
FIGURE 6.1 COMPARISON OF THE WHOLESALE AND DTP ROUTES OF DISTRIBUTION
FIGURE 7.1 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: GLOBAL MARKET FORECASTS ($BN) BY SUBMARKET, 2018-2030
FIGURE 7.2 LEADING NATIONAL PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKETS: REVENUE PROJECTIONS ($BN), 2018, 2025 AND 2030
36.6
AAH Pharmaceuticals
AccessClosure
Acofarma (Asociación Cooperativas Farmacéuticas)
ADG Apotheken-Dienstleistungsgesellschaft mbH
Admenta
Alfresa Fine Chemical Corporation
Alfresa Holdings
Alliance Boots
Alliance Healthcare
Alliance Santé
Alliance UniChem
AmeriSource Health
AmerisourceBergen
AmerisourceBergen Canada
AmerisourceBergen Drug Corporation (ABDC)
AmerisourceBergen specialty Group (ABSG)
Apollo Medical Holdings
ASTEC Co., Ltd.
ASTIS Co., Ltd.
Athos Farma
ATOL CO., LTD.
Azwell
Bayer
BENU Apotheek
Bergen Brunswig
Biologics Inc
Boots Group
Bristol-Myers Squibb
Brocacef Groep NV
Brocacef Holding
Bundesverband des Pharmazeutischen Grosshandel
Cardinal Health
Caremark Rx
Celesio AG
CERP Bretagne Nord
CERP Rhin Rhone Mediterranee
CERP Rouen
Chiyaku Co
Chuounyu Co., Ltd.
Cloumed Corporation
Cofares
Comifar
Cordis
CoverMyMeds
CoverMyMeds LLC
CVS Caremark
CVS Corporation
CVS Health Corporation
Cystic Fibrosis Foundation Pharmacy, LLC
Daiichi Sankyo Propharma Co.
Dong Ying (Jiangsu) Pharmaceuticals Co., Ltd.
Drogarias Tamoio
Drug Trading Company Ltd
Dutch ACM
Emart Company
ENSHU YAKUHIN CO., LTD.
Ethicon
EVERLTH AGROTECH Co., Ltd.
EVERLTH Co., Ltd.
Farcopa Distribuzione
Fukujin Co.
Good Service Co
Guangzhou Pharmaceutical Company Ltd.
Guangzhou Pharmaceuticals Corporation
Harvard Drug
Hedef Alliance
Hefame
HEISEI YAKUHIN CO., LTD.
IZUTSU KURAYA SANSEIDO Inc.
IZUTSU PHARMACEUTICAL CO. LTD.
Japanese Pharmaceutical Wholesalers Association
Jingu Yakuhin Co., Ltd.
Johnson & Johnson
Katren
Kenzmedico Co., Ltd.
Kerr Drug
KOBASHOU. CO., LTD.
KURAYA SANSEIDO Inc
Life Medicom Co., Ltd.
Lloyds Pharmacy
MARUZEN YAKUHIN CO., LTD.
McKesson
McQueary Brothers of Springfield
Medical Specialties Distributors
MEDICEO CORPORATION
Medicine Shoppe Canada Inc.
MEDIE Co., Ltd.
MEDIPAL HOLDINGS CORPORATION
Mediq Apotheken Nederland B.V.
Medtronic
Meinan Distribution Center
Metro Medical Supply Inc
Mitsubishi
MM CORPORATION
MP AGRO CO., LTD.
MVC CO., LTD
MWI Veterinary Supply, Inc.
Nadro
Nakano Yakuhin Co., Ltd.
National Health Service (NHS)
National Pharmaceutical Pricing Authority (NPPA)
Nihon Apoch Co.
Novo Nordisk
Novodata Zrt.
Numark
OCP
Oncology Therapeutics
Oncoprod
OptumRx
P.J.D. Network
PALTAC CORPORATION
Paltac Corporation
Paltac Corporation
PALTAC KS CORPORATION
Panpharma
Pfercos Co., Ltd.
Pfizer
PharMEDium
Polska Grupa Farmaceutyczna
Profarma
Prosper
Protek
PSC Co, Ltd.
PSS World Medical Inc.
Ratiopharm
RDC Kanto5
Red Oak Sourcing
Red Oak, LLC
Rexall Health
Rite Aid Corporation
Rosta
RxCrossroads
S. D.Collabo Co.,Ltd.
S.D.Logi CO., Ltd.
Sakurai Tsusho Corporation
Sanacorp
Sandoz
Sanki Corporation
Sanki MediHeart Limited
Sanki Wellbe
Sanki Wellbe Co., Ltd.
Sannova
Sanwa Kagaku Kenkyusho Co., Ltd.
S-Care Mate Co., Ltd.
Sciclone Trade
SEIWA SANGYO CO
Shanghai Fosun Pharmaceutical
Shanghai Pharma Zhenjiang Co., Ltd.
Shanghai Pharmaceutical Holdings
Shinohara Chemicals
Shinsegai Group
Shoyaku Co., Ltd.
SIA International
Sincamesp
SINOPHARM
S-mile, Inc
Sonexus Health
SPH Jiangxi Shangrao Pharmaceutical Co., Ltd.
SPH Keyuan Xinhai Pharmaceutical Hebei Co., Ltd.
SPH Keyuan Xinhai Pharmaceutical Heilongjiang Co., Ltd.
SPLine Corporation
SUZUKEN
Suzuken Co., Ltd.
Suzuken Iwate Co., Ltd.
Suzuken Medical Instruments Co, Ltd
Suzuken Okinawa Yakuhin Co., Ltd.
The PHOENIX Group
Toho Holdings
Tokiwa Yakuhin Co
Torfarm
Tradex International
TS Alfresa Corporation
UniChem
US Oncology Holdings, Inc.
USHIODA KURAYA SANSEIDO Inc.
USHIODA SANGOKUDO YAKUHIN CO., LTD.
Vaccine Safe Co
Vantage Oncology
Victoria Merger Sub, Inc.
Vitaco Holdings
Walgreen
Walgreens Boots Alliance
World Courier Group Inc.
Wyeth Pharmaceuticals
YAMAHIRO KURAYA SANSEIDO Inc.
Yunnan Pharmaceutical Co., Ltd.
Zuellig Pharma
